Log in

Relevant bibliographies by topics / Bispecific; BsAb; T cells

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers

Academic literature on the topic 'Bispecific; BsAb; T cells'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bispecific; BsAb; T cells.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bispecific; BsAb; T cells"

1

Link, BK, and GJ Weiner. "Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells." Blood 81, no. 12 (1993): 3343–49. http://dx.doi.org/10.1182/blood.v81.12.3343.bloodjournal81123343.

Full text

Abstract:

Bispecific monoclonal antibodies (bsabs) recognizing both CD3 and a tumor antigen can redirect T-cell-mediated cytotoxicity toward cells bearing that antigen. Such bsabs have been shown to be more effective than monospecific monoclonal antibodies (MoAbs) at preventing tumor growth in animal models of B-cell malignancy. The current studies describe the production and preliminary evaluation of a bsab designed to induce the lysis of malignant human B cells by human T cells. The bsab was obtained from a hybrid-hybridoma cell line produced by fusing OKT3-secreting hybridoma cells with hybridoma cel

APA, Harvard, Vancouver, ISO, and other styles

2

Link, BK, and GJ Weiner. "Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells." Blood 81, no. 12 (1993): 3343–49. http://dx.doi.org/10.1182/blood.v81.12.3343.3343.

Full text

Abstract:

Abstract Bispecific monoclonal antibodies (bsabs) recognizing both CD3 and a tumor antigen can redirect T-cell-mediated cytotoxicity toward cells bearing that antigen. Such bsabs have been shown to be more effective than monospecific monoclonal antibodies (MoAbs) at preventing tumor growth in animal models of B-cell malignancy. The current studies describe the production and preliminary evaluation of a bsab designed to induce the lysis of malignant human B cells by human T cells. The bsab was obtained from a hybrid-hybridoma cell line produced by fusing OKT3-secreting hybridoma cells with hybr

APA, Harvard, Vancouver, ISO, and other styles

3

Velasquez, Mireya Paulina, Challice L. Bonifant, and Stephen Gottschalk. "Redirecting T cells to hematological malignancies with bispecific antibodies." Blood 131, no. 1 (2018): 30–38. http://dx.doi.org/10.1182/blood-2017-06-741058.

Full text

Abstract:

Abstract There is a need to improve outcomes for patients with recurrent and/or refractory hematological malignancies. Immunotherapy holds the promise to meet this need, because it does not rely on the cytotoxic mechanism of conventional therapies. Among different forms of immunotherapy, redirecting T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy. BsAbs are an “off-the-shelf” product that is easily scalable in contrast to adoptive T-cell therapies. Among these, the bispecific T-cell engager blinatumomab has emerged as the most successful BsAb

APA, Harvard, Vancouver, ISO, and other styles

4

He, Xiao, Yanliang Zhang, Yun Wei Lai, et al. "Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody." Blood 134, Supplement_1 (2019): 4463. http://dx.doi.org/10.1182/blood-2019-131540.

Full text

Abstract:

Introduction: Multiple Myeloma (MM) and Non-Hodgkin Lymphoma (NHL) are hematologic malignancies that remain difficult to treat. While autologous CAR-T cell therapies have shown promise in treating these diseases, these therapies are not without issues, including lack of response in many patients, lengthy time to produce CAR-T cells, occasional production failures, as well as high manufacturing costs. As an alternative approach, protein-based T cell engaging and redirecting bispecific antibodies (BsAbs) have been developed. We have generated anti-CD38/CD3 BsAbs to redirect T cells against CD38,

APA, Harvard, Vancouver, ISO, and other styles

5

DiLillo, David J., Kara Olson, Katja Mohrs, et al. "A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells." Blood Advances 5, no. 5 (2021): 1291–304. http://dx.doi.org/10.1182/bloodadvances.2020002736.

Full text

Abstract:

Abstract CD3-engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells are potent therapeutic approaches for redirecting patient T cells to recognize and kill tumors. Here we describe a fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR T cells to identify differences in efficacy and mechanism of action. In vitro, BCMAxCD3 bsAb efficiently induced polyclonal T-cell killing of primary human plasma cells and multiple myeloma (MM) cell lines expressing a range of BCMA cell surf

APA, Harvard, Vancouver, ISO, and other styles

6

Sun, Rui, Yuexian Zhou, Lei Han, et al. "A Rational Designed Novel Bispecific Antibody for the Treatment of GBM." Biomedicines 9, no. 6 (2021): 640. http://dx.doi.org/10.3390/biomedicines9060640.

Full text

Abstract:

Epidermal growth factor receptor variant III (EGFRvIII) is highly and specifically expressed in a subset of lethal glioblastoma (GBM), making the receptor a unique therapeutic target for GBM. Recently, bispecific antibodies (BsAbs) have shown exciting clinical benefits in cancer immunotherapy. Here, we report remarkable results for GBM treatment with a BsAb constructed by the “BAPTS” method. The BsAb was characterized through LC/MS, SEC-HPLC, and SPR. Furthermore, the BsAb was evaluated in vitro for bioactivities through FACS, antigen-dependent T-cell-mediated cytotoxicity, and a cytokine secr

APA, Harvard, Vancouver, ISO, and other styles

7

Demanet, C., J. Brissinck, J. De Jonge, and K. Thielemans. "Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation." Blood 87, no. 10 (1996): 4390–98. http://dx.doi.org/10.1182/blood.v87.10.4390.bloodjournal87104390.

Full text

Abstract:

The BCL1 lymphoma in Balb/c mice can be successfully treated with bispecific (anti-CD3 x anti-idiotype) antibodies (BSABs). In these experiments, animals were injected intraperitoneally (IP) with 5 x 10(3) tumor cells (day 0) and treated with one single intravenous (IV) injection of 5 micrograms BSAB (day 9). Because cross-linking of the CD3 complex is not in itself sufficient to activate resting T cells, the therapeutic success was mainly based on the progressive retargeting of the relatively small cytotoxic T-lymphocyte effector cell pool already in existence in vivo. For this reason, the th

APA, Harvard, Vancouver, ISO, and other styles

8

Koristka, Stefanie, Marc Cartellieri, Anke Theil, et al. "Antigen-Specific Redirection of Human Regulatory T Cells by Bispecific Antibodies,." Blood 118, no. 21 (2011): 4041. http://dx.doi.org/10.1182/blood.v118.21.4041.4041.

Full text

Abstract:

Abstract Abstract 4041 Hematopoietic stem cell transplantation is a commonly used treatment for various hematological malignancies. However, a life-threatening complication following this therapy is the development of Graft versus Host Disease (GvHD), during which transplanted donor immune cells attack the host and lead to severe inflammatory responses and tissue damage. Given the key role of regulatory T cells (Tregs) in immune homeostasis and peripheral tolerance, the adoptive transfer of these cells may represent a promising therapeutic opportunity for the treatment of GvHD. This approach h

APA, Harvard, Vancouver, ISO, and other styles

9

Lin, Tsung-Yi, Jeong A. Park, Alan Long, Hong-Fen Guo, and Nai-Kong V. Cheung. "Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy." Journal for ImmunoTherapy of Cancer 9, no. 9 (2021): e003114. http://dx.doi.org/10.1136/jitc-2021-003114.

Full text

Abstract:

BackgroundThe prognosis for metastatic Ewing sarcoma family of tumors (EFT) is still poor despite high-dose chemotherapy and radiation treatment. Immunotherapies hold promise, but cancer antigen-targeting immunotherapies have largely failed to induce effective T cell receptor-mediated antitumor response. However, T cell-engaging bispecific antibodies (T-BsAbs) have yet to be adequately explored.MethodsRehumanized STEAP1-IgG was used to build T-BsAb (named BC261) using the 2+2 IgG-[L]-scFv platform carrying the anti-CD3 huOKT3 scFv as the second specificity. Its binding epitope mapping, species

APA, Harvard, Vancouver, ISO, and other styles

10

Santich, Brian H., Jeong A. Park, Hoa Tran, Hong-Fen Guo, Morgan Huse, and Nai-Kong V. Cheung. "Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies." Science Translational Medicine 12, no. 534 (2020): eaax1315. http://dx.doi.org/10.1126/scitranslmed.aax1315.

Full text

Abstract:

T cell–bispecific antibodies (BsAbs) couple cytotoxic T lymphocytes to tumor cells, inducing their destruction. Although there are more than 60 classes of BsAbs in development, the relative importance of parameters such as interdomain spacing or spatial configuration is largely unknown. Here, we dissected a symmetric dual bivalent BsAb platform (IgG-[L]-scFv: antitumor IgG with anti-CD3 scFv fused to the light chains) to explore the importance of valency and spatial configuration for BsAb-induced T cell cytotoxicity. Our results revealed that placing tumor and T cell binding domains on the sam

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Bispecific; BsAb; T cells"

1

Honeychurch, Jamie. "Engineered antibodies in the treatment of B cell lymphoma." Thesis, University of Southampton, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.340341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gohil, Satyen Harish. "Pre-clinical development of novel ROR1 chimeric antigen receptor T cells and bispecific T cell engagers." Thesis, University College London (University of London), 2018. http://discovery.ucl.ac.uk/10042372/.

Full text

Abstract:

Receptor tyrosine kinase like orphan receptor 1 (ROR1) is an onco-embryonic antigen present on a range of solid and haematological malignancies, including chronic lymphocytic leukaemia. Additionally, limited, low level expression on normal tissues makes it an attractive therapeutic target. Chimeric antigen receptor T cells and Bispecific T Cell Engagers have emerged as exciting immunotherapeutic approaches, utilising the inherent cytotoxic potential of autologous T cells to yield demonstrable benefit for patients. We therefore aimed to generate novel ROR1 CAR T cells and BiTEs. Following a rat

APA, Harvard, Vancouver, ISO, and other styles

3

McBride, Harry Michael. "The recruitment of ribosomal inactivating protein or T cells by antibody derivatives in the treatment of B cell lymphoma." Thesis, University of Southampton, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.295851.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kauer, Joseph [Verfasser], and Gundram [Akademischer Betreuer] Jung. "The role of stimulating bystander cells in bispecific antibody-mediated T cell activation / Joseph Kauer ; Betreuer: Gundram Jung." Tübingen : Universitätsbibliothek Tübingen, 2018. http://d-nb.info/1198973714/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Brozy, Johannes [Verfasser], Arne [Akademischer Betreuer] Skerra, and Patrick A. [Akademischer Betreuer] Baeuerle. "Novel T Cell-Engaging, Bispecific Antibodies for Depletion of Human Immunodeficiency Virus-Infected Cells / Johannes Brozy. Gutachter: Arne Skerra ; Patrick A. Baeuerle. Betreuer: Arne Skerra." München : Universitätsbibliothek der TU München, 2015. http://d-nb.info/1070981451/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Harris, Michael James. "Development of an optogenetic toolkit for the interrogation of T cell signalling dynamics." Thesis, University of Cambridge, 2018. https://www.repository.cam.ac.uk/handle/1810/274251.

Full text

Abstract:

T cells are a cornerstone of the mammalian adaptive immune system. A range of T-cell subsets exist that can orchestrate the overall immune response to pathogens or cancers, either by directly killing infected cells or licensing other cells to do so. Dysregulation of this important process can result in immunodeficiency or autoimmunity. Although T cells have been studied extensively over many decades, the detailed mechanisms underlying T-cell activation remain to be fully resolved. This thesis describes the development of new optogenetic approaches for the modulation of T-cell signalling dynami

APA, Harvard, Vancouver, ISO, and other styles

7

Benmebarek, Mohamed-Reda [Verfasser], and Sebastian [Akademischer Betreuer] Kobold. "Characterization of bispecific antibodies that drive synthetic agonistic receptor-transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models / Mohamed-Reda Benmebarek ; Betreuer: Sebastian Kobold." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2021. http://d-nb.info/1235325873/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lee, Yi-Ting, and 李依庭. "Development of novel bispecific antibody to enhance therapeutic effect of T cells against EGFR-expressing triple negative breast cancer." Thesis, 2019. http://ndltd.ncl.edu.tw/handle/cd3wbb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ptáčková, Pavlína. "Příprava a charakterizace chimerických antigenních receptorů." Doctoral thesis, 2021. http://www.nusl.cz/ntk/nusl-447132.

Full text

Abstract:

Background: The CD19 chimeric antigen receptor (CAR) adoptive T-cell therapy for B-cell leukemia is a promising treatment for relapsed or refractory malignities. The overall response rate of CD19 CAR-T cells in clinical trials was greater than 80% for patients with B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin's lymphoma (NHL). However, CAR-T cell therapy of leukemias and solid tumors has been limited by a lot of factors such as antigen loss of tumor escape variants, reduced proliferation, persistence and tumor-infiltration of CAR-T cells in vivo, immunosuppressive tumor environm

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Bispecific; BsAb; T cells"

1

Lum, Lawrence G., and Archana Thakur. "Bispecific Antibodies for Arming Activated T Cells and Other Effector Cells for Tumor Therapy." In Bispecific Antibodies. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-20910-9_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Thakur, Archana, Lawrence G. Lum, and Sandeep Mittal. "Bispecific Antibody Armed T Cells to Target Cancer Cells." In Methods in Molecular Biology. Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7553-2_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Di Mauro, Mary E., and Ann Ager. "T-Lymphocyte Proliferation Stimulated by αβTCR/CD2 Bispecific Antibody is Dependent on LFA- 1/ICAM-1 Recognition of Accessory Cells." In Advances in Experimental Medicine and Biology. Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1971-3_85.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Lum, Lawrence G., and Pamela A. Davol. "Retargeting T cells and immune effector cells with bispecific antibodies." In Cancer Chemotherapy and Biological Response Modifiers Annual. Elsevier, 2005. http://dx.doi.org/10.1016/s0921-4410(04)22013-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hirabayashi, Koichi, Gianpietro Dotti, and Barbara Savoldo. "Cancer Immunotherapy in Children." In Oxford Textbook of Cancer in Children. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198797210.003.0008.

Full text

Abstract:

This chapter discusses the principle of cancer immunotherapy in children and adolescents, starting with the most common form of cellular immunotherapy: allogeneic haematopoietic stem-cell transplantation (HSCT). It then discusses specific immunotherapy strategies based on the administration of classic monoclonal antibodies (mAbs) targeting tumour-associated antigens, novel bispecific antibodies that simultaneously target tumour-associated antigens and activate CD3<sup>+</sup> T lymphocytes, and mAbs that block key inhibitory molecules of the immune system (checkpoint blockade). Finally, the chapter describes specific cellular immunotherapy approaches, such as tumour vaccine and adoptive transfer of immune cells. Although only a few immunotherapies have so far been incorporated into the standard practice for paediatric cancers, their role is enjoying a new revival, after the promising results obtained in recent clinical trials.

APA, Harvard, Vancouver, ISO, and other styles

6

Zwaan, Michel, Gareth J. Veal, and Lucas Moreno. "Chemotherapy and Other Anti-Cancer Drugs." In Oxford Textbook of Cancer in Children. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198797210.003.0003.

Full text

Abstract:

Chemotherapy plays a prominent role in the treatment of paediatric malignancies. Several pharmacokinetic and pharmacodynamic mechanisms must be taken into account when administering chemotherapy. These mechanisms may contribute to the clearance, toxicity, and/or efficacy of cytotoxic drugs. Examples are age, sex, body composition, genetic polymorphisms, and co-administered drugs. A new era of childhood cancer treatment is emerging, characterized by the development of new agents resulting from advances in molecular biology. Directing drugs against the abnormalities identified only in tumour cells is known as targeted therapy. Such compounds ought to have better anti-tumour activity and improved safety profiles. Monoclonal antibodies are becoming more important, especially in the treatment of haematological malignancies, but also in neuroblastoma. Moreover, other advances in immunotherapy, with bispecific T-cell engaging (BITE) antibodies and chimeric-antigen receptor T-cells for example, are rapidly changing the landscape of available therapies to treat childhood cancer. After a long period during which there were very few registrations of new drugs for use in children, the regulatory incentives introduced in both North America and Europe now stimulate research directed towards the identification and evaluation of new drugs in paediatric oncology.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bispecific; BsAb; T cells"

1

Smith, Victoria, Sterling Eckard, Michael P. Rettig, et al. "Abstract 5699: AMV564, a bivalent, bispecific T-cell engager, depletes myeloid-derived suppressor cells and activates T cells in cancer patients." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5699.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mathur, Divya, Adam Root, Bozena Bugaj-Gaweda, et al. "Abstract A16: A GUCY2c-CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 17-20, 2019; Boston, MA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm19-a16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mathur, Divya, Adam Root, Bozena Bugaj-Gaweda, et al. "Abstract 2283: A novel GUCY2C - CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-2283.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Münz, Markus, Alexander Murr, Petra Hoffmann, et al. "Abstract 4841: Lysis of cancer cells by highly purified T regulatory cells engaged via an EpCAM/CD3-bispecific BiTE antibody." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4841.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Zhukovsky, Eugene A., Uwe Reusch, Carmen Burkhardt, et al. "Abstract 1243: Bispecific TandAbs: a safe and potent platform for T cell-mediated killing of CD19+cells." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1243.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Dovedi, Simon J., Yariv Mazor, Matthew Elder, et al. "Abstract 2776: MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2776.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Rossi, Diane L., Thomas M. Cardillo, Edmund A. Rossi, Maria Zalath, David M. Goldenberg, and Chien-Hsing Chang. "Abstract 2655: A novel Trop-2/CD3 trivalent bispecific antibody effectively redirects T cells to kill target human pancreatic and gastric cancer cells." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2655.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Moore, Paul A., Wenjun Zhang, Jonah Rainey, et al. "Abstract 5629: Application of a novel bispecific antibody-based scaffold for optimal redirected T-cell killing of cancer cells." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-5629.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Park, Jeong A., Hong Xu, Irene Cheung, and Nai-Kong V. Cheung. "Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy." In Abstracts: AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; December 3-6, 2017; Atlanta, Georgia. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.pedca17-b38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bosch, Jacobus J., Sabine Rödel, Michael Aigner, et al. "Abstract 5621: MCSP/CD3-bispecific single-chain antibody construct engages CD4+and CD8+T cells for lysis of MCSP-expressing human uveal melanoma cells." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-5621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!